We investigated the effect of ursodeoxycholic acid on major histocompatibility complex class I gene expression in cultured human hepatoma cells. Ursodeoxycholic acid, which is now being used for the treatment of various autoimmune liver diseases, paradoxically increased the mRNA level of major histocompatibility complex class I. However, endogenous bile acids, for example, chenodeoxycholic acid, increased major histocompatibility complex class I mRNA expression more strongly compared with ursodeoxycholic acid. Concerning the interplay between ursodeoxycholic and ehenodeoxycholic acids, these bile acids additively induced major histocompatibility complex class I mRNA expression. In contrast, when the total concentration of ursodeoxycholic and chenodeoxycholic acids was kept constant, the expression of major histocompatibility complex class I mRNA appeared to decrease in a dose-dependent manner with an increasing ratio of ursodeoxycholic acid. These findings indicate that the beneficial action of ursodeoxycholic acid may be related to this relative decrease in major histocompatibility complex class I gene expression.
Introduction
Primary biliary cirrhosis (PBC) is a chronic and progerssive cholestatic disease predominantly affecting middle-aged women. 1'2 In patients with PBC, as opposed to normal subjects, the up-regulated expression Offprint requests to: H. Tanaka (Received for publication on Jan. 26, 1995 ; accepted on Apr. 28, 1995) of major histocompatibility complex (MHC) class I antigens on hepatocyte membrances and an aberrant expression of MHC class II antigens on bile duct epithelium have been reported. [3] [4] [5] In particular, increased MHC class I antigens have been shown to be expressed in areas of piecemeal necrosis, and to be seen in the later stages of PBC. 6 Further, it is known that the infiltrating lymphocytes in the lesions showing piecemeal necrosis and/or intralobular necrosis in patients with PBC are predominantly cytotoxic T lymphocytes. 7's Thus, the increase in MHC class I expression may be directly associated with hepatocyte injury that is mediated by cytotoxic T lymphocytes.
In general, it is well known that hydrophobic bile acids, such as chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), and lithocholic acid (LCA), are hepatic toxins, as evidenced in laboratory animals in vivo, 9-11 in perfused livers, ~2 and in isolated hepatocytes from human beings.13"14 Therefore, it is possible that endogenous bile acids, e.g., CDCA, DCA, and LCA, cause secondary hepatocellular injury by hepatocytotoxic and/or immune-mediated mechanisms. 5 In experiments in rats, it has also been shown that cholestasis itself, induced by ligation of the extrahepatic bile duct, leads to an increased expression of MHC class I antigens on hepatocytes. ~5 Ursodeoxycholic acid (UDCA) on the other hand, is considered to be a nonhepatotoxic hydrophilic bile acid that may reverse the potential hepatotosxicity of endogenous bile acids, and it is often used in patients with cholestasis to improve liver dysfunction. 16-1s Notably, a beneficial effect of UDCA in patients with PBC has been demonstrated in double-blind controlled studies. In those studies, UDCA was shown to improve biochemical parameters. 19-21 Calmus et al., s using immunocytochemical techniques, reported that UDCA significantly decreased MHC class I molecules on hepatocytes in patients with PBC. Terasaki et al. 2a reported that treatment with UDCA not only decreased the hepatocellular expression of MHC class I antigens but that it also reduced the hepatoceltutar infiltration of activated T tymphocytes in patients with PBC. However, experimental evidence to confirm immunomodulatory action of UDCA is completely lacking. Since UDCA is an isomer of CDCA, the mutually exclusive interaction between these two bite acids appears to be extremely interesing. Recently, we demonstrated that CDCA, one of the major constituents of bile acids in cholestasis, 5 directly increased both the immunoreativity and mRNA levels of MHC class I in human cultured hepatoma cetls, 23 indicating that cholestasis itself may influence immune regulation in the hepatobiliary system. Moreover, Hillaire et al. z4 recently confirmed our finding in a study of normal human hepatocytes. More recently, we showed that MHC class I mRNA expression was induced by CDCA in cultured human hepatoma cells via the activation of a protein kinase C-dependent pathway. -~s Given this background, we studied the effect of UDCA on MHC class I gene expression. We report here that, in HepG2 cells, UDCA as well as other bile acids induces MHC class I mRNA expression, but decreases CDCA-induced MHC class I mRNA expression.
Materials and methods

Cel/s
The human hepatoma cell line HepG2 was cultured in Dulbecco's modified Eagle's medium (GIBCO BRL, New York, N.Y.) supplemented with 0.1raM nonessential amino acids, 10% fetal calf serum (GIBCO BRL), t00 gg/mt penicillin, and 100 U/ml streptomycin at 37~ in a humidified atmosphere of 5% CO2 in air. Serum steroids were stripped with dextran-coated charcoal before use.
Ligands
Sodium salts of UDCA and CDCA were kindly gifted by Tokyo Tanabe Co. (Tokyo, Japan). These bile acids were dissolved in ethanol. Gachromatography demonstrated that the composition of all bile acids had a purity of at least 99.5%. These bile acids were used at final concentrations of 10-250gM, since the sermn concentration of UDCA in patients with PBC undergoing UDCA treatment is reported to be around 10-100 ltlM. [26] [27] [28] 
RNA isolation
Total RNA was isolated according by the method of acid guanidinium-thiocyanate-phenol-chloroform (AGPC) extraction. 29 Briefly, HepG2 cells were cullured in 100-mm diameter plastic dishes (Iwaki Glass, Funabashi, Japan), in the absence or presence of bile acids, for various time periods~ After being washed twice with PBS, the cells were lyzed with a solution that contained 4M Fluka-purum grade guamdinium thiocyanate (Tridom Inc., New York, N:Y.), 25ram sodium citrate, pH 7.0, 0.5% sodium N-laUroyt= sarcosine, and 0.1M 2-mercaptoethanoL RNA was further purified by phenol/chloroform extraction and then precipitated in isopropanol. RNA pel!ets were solubilized in diethylpyrocarbonate-treated filtered water and the concentration of RNA was:determine d spectrophotometricalty.
Northern blot hybridization
Northern blot analysis was done as described previously. 2~25 In brief, 20/ag of total RNA, denatured in a loading buffer by heating at 70~ for 5rain, was separated on a 1% formaldehyde-agarose gel. The fractionated RNA was immobilized on a charge-modified polyvinylidene fluoride (PVDF) membrane (lmmobilon-N; Miltipore, Bedford Mass.), using a pressure blot apparatus (Stratagene, Lajolla Calif.), and RNA was cross-linked by means of ultraviolet (UV)irradiation. The plasmid pDP001 was kindly provided by the Japanese Cancer Research Resources Bank (JCRB) and the 0.4-kbPvu II-Pst I DNA fragment was used as the cDNA probe for HLA-BT, as described previouslyY ~25"3~ The cDNA probe for ~-actin was from Cleveland et al. 31 These cDNA probes (25-50 ng) wer e labeled with [a,32p]dCTP (3000Ci/mmot, Amersham, Buckinghamshire, UK), using a BcaBEST labeling kit (TaKaRa, Kyoto, Japan) according to the manufacturer's protocol. The membrane was prehybridized with a QuikHyb hybridization solution (Stratagene) for 15 min at 68~ and was hybridized to 2 • 1106 Cpm/m~ of 32p-labeled probes for 60rain at 68~ After the membrane was washed for 30rain in 0.!% sodium dodecyl sulfate (SDS) with 2 X saline sodium citrate (SSC) at 25~ and for an additional 30rain in 0.t% SDS with 0.11 • SSC at 60~ radioactivity on the membrane was quantified with a Biolmaging Analyzer, BAS2000 (Fujix, Tokyo, Japan) and then the membrane was exposed to X=ray film (Hyperfihn-MPi Amersham) with intensifying screens (Kodak, Tokyo, Japan) at -70~ overnight.
Statistical ana(ysis
All values in this study were expressed as means +_ SE. Comparisons were made using analysis of variance-(ANOVA), followed by two-tailed Student:s t:test. Differences were considered significant if P values were less than 0.05.
Results
Northern blot analysis of MHC class I gene expression
We have already demonstrated that C D C A increased M H C class I m R N A (Fig. 1) . 23 To assess whether U D C A induces M H C class I m R N A expression as well, Northern blot analysis was performed. Treatment with increasing concentrations of U D C A revealed an apparent elevation of M H C class I m R N A (Fig. 2) . Such U D C A effect appeared to be dose-dependent up to 100~tM (Fig. 2) ; however, at 250gM of U D C A , the expression of M H C class I m R N A was slightly decreased, possibly due to a decrease in cell viability (data not shown). A time course study showed that the level of M H C class I m R N A seemed to be significantly increased in a time-dependent manner (Fig. 3) . The maximal effect of U D C A on M H C class I m R N A expression was observed at 48h (Fig. 3) . At 72h of treatment with U D C A , M H C class I m R N A expression was decreased, although cell viability was intact (Fig.  3) . Overall U D C A induced M H C class I m R N A expression in a dose-and time-dependent manner similarly to C D C A (Fig. 1) 23 However, quantitative analysis demonstrated that, at 100~tM, U D C A was a weaker inducer of M H C class I m R N A than C D C A (Fig. 1) . To address this issue, we studied the effects of these two bile acids on MHC class I mRNA expression. First, we examined the effect of various concentrations of UDCA on the CDCA-induced levels of MHC class I mRNA . As shown in Fig, 4 , UDCA additivety and dose-dependently enhanced MHC class I mRNA expression in the presence of various concentrations of CDCA. However, the effect of UDCA was relatively weak, e.g,, 10gM of CDCA had a stronger effect on MHC class I mRNA expression than t00gM of UDCA (Fig. 4) . Secondly, we studied the effect of bile acid composition, keeping the total bile acid concentration constant. When the ratio UDCA was increased, MHC class I mRNA expression was decreased (Fig. 5) . Therefore, we suggest that, once replacement between UDCA and CDCA occurs in vivo, UDCA reduces MHC class I mRNA expression relative to that seen with CDCA.
Discussion
The present study suggests, for the first time, that, in addition to CDCA, UDCA increases the mRNA level of MHC class I in HepG2 cells. We used unconjugated forms of bile acids at concentrations of 0-250gM; covering the range of tissue bile acid concentrations commonly observed during chronic cholestasis.32 Atthough hepatocytes are also exposed to the conjugated forms of bile acids, which have less marked toxic effects than the unconjugated forms,33'34 our results can reasonably be extrapolated to the in vivo situation, because the contact time between hepatoma cells and bite acids was much shorter under our in vitro conditions than during cholestasis, t5 In addition, we showed that, in: our experimental system in HepG2 cells, UDCA enhanced the CDCA-induced MHC class I mRNA expression. When the total bite acid concentration of CDCA and UDCA in the culture medium was kept constnat, and the ratio of UDCA was increased~ MHC class I mRNA expression was decreased. Thus, the relative decrease of MHC class I mRNA expression in HepG2 cells brought about by UDCA may result not only from a reduction in the intrahepatic accunmlation of cytotoxic bile acids such as CDCA, but also from a reduction in immunological injury. However, we cannot rule out the possibilities that: (i) the net degree of hydrophobic-hydrophilic balance is reduced by the coating of the hydrophobic site on CDCA molecules with UDCA in the culture medium, and (ii) that MHC class 1 expression is rather differently regulated in nonmalignant cells. For further confirmation, studies with primary hepatocyte cultures are necessary. We have recently reported the ascending order of MHC class I mRNA inducibility by bile acids to be: UDCA, CA, CDCA, DCA, and LCA. 25 In addition, the inducibility of MHC class I mRNA was clearly correlated with the hydrophobicity of the corresponding bile acids. 2s Quist et al. 35 report that histamine release from mast cells correlates highly with the hydrophobicity of bile acids. 35 They showed that the order of potency for histamine release for CDCA and DCA was unconjugated > glycine conjugated > taurine conjugated. 35 Thus, these reports strongly support the notion that the hydrophobicity of bile acids may be related to alterations in certain biological functions, including MHC class I gene regulation. We also need to further study the inducibility of MHC class I mRNA by the conjugated forms of UDCA and CDCA.
From the clinical viewpoint, it is of extreme importance to assess whether UDCA acts as an immune modulator in vivo. Batta et al. 20 investigated the effect of UDCA on bile acid metabolism in both patients with PBC and in healthy subjects. They found that the mean serum concentration of total bile acids following treatment with 900mg/day of UDCA was 8jaM in healthy subjects, while it was 78p.M in patients with PBC. 36 We showed that, at 10 ~tM of UDCA, levels of MHC class I mRNA were only marginally changed compared with basal levels. Therefore, it is unlikely that UDCA affects the expression of MHC class I antigen in healthy subjects. On the contrary, in patients with cholestasis, it is probable that endogenous bile acids markedly increase the expression of MHC class I antigen, since the mean serum concentration of total bile acids in patients with PBC is virtually comparable with the concentration of bile acids that induce MHC class I mRNA expression. It can be speculated that the useful effects of long-term administration of UDCA in patients with PBC are related to the replacement of hydrophobic endogenous bile acids with hydrophilic UDCA in patients' sera. 37 Batta et al. 26 examined the effect of UDCA on urinary and serum bile acids in patients with PBC. They demonstrated that the beneficial effect of UDCA may be due to a reduction of the hydroxylated derivatives of endogenous bile acids, together with the appearance of the hydroxylated derivative of UDCA, or that the effect may be due to the displacement of the more hydrophobic endogenous bile acids by the hydrophilic UDCA. 26 In addition, they indicated that after UDCA treatment in patients with PBC, the serum concentration of total bile acids was decreased compared with serum concentration before UDCA treatment, although the urinary concentration of total bile acids after UDCA treatment in these patients was significantly increased. 26 Crosignani et al. 28 reported that, in patients with PBC, UDCA modified the composition of the bile acid pool by inhibiting the ileal absorption of endogenous bile acids. They suggested that the substitution of CA with UDCA would explain the decrease in the relative hepatotoxicity index of the bile acid pool after UDCA administration, although serum total bile acid concentrations were unchanged after treatment with UDCA. Under our in vitro conditions, UDCA additively increased the effect of CDCA on MHC class I mRNA expression; however, when the total bile acid concentration was constant, an increased ratio of UDCA brought about a relative decrease in MHC class I mRNA expression. Therefore, it is suggested that the beneficial effect of UDCA in clinical situations cannot be ascribed to competition between endogenous bile acids and UDCA at the target cell level, but, rather, to a relative reduction in the endogenous bile acid concentration after long-term administration of UDCA. 26 '36 Recently, several groups have investigated the effect of long-term administration of UDCA on symptoms, serum markers of cholestasis, histology, and the need for liver transplantation in patients with PBC. 38-~~ Poupon and the UDCA-PBC study group 38 reported that long-term UDCA therapy slowed the progression of PBC and rduced the need for liver transplantation, although they stated that further studies were required to assess the additional benefit of combined medical treatments, such as UDCA plus immunosuppressive agents. On the contrary, Lindor et al. 39 and Heathcote et al. 4~ reported that UDCA treatment in patients with PBC did not significantly improve patient survival and need for liver transplantation. These reports suggested that combination therapy with UDCA and other agents, e.g., immunosuppressive drugs, is needed for patients with PBC, although UDCA therapy may slow the progression of PBC. Thus, the combined effects of UDCA with other drugs should be examined in further studies.
In conclusion, we demonstrated that the mRNA level of MHC class I was up-regulated by UDCA. Since UDCA had a weaker effect on MHC class I mRNA expression than CDCA, it is possible that one of the beneficial actions of UDCA in patients with PBC may be related to a relative decrease in MHC class I expression, probably, due to replacement the hepatotoxic hydrophobic endogenous bile acids.
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